article thumbnail

Better Artificial Intelligence (AI) Stock: Nvidia vs. Micron Technology

The Motley Fool

In this article, we will take a closer look at the prospects and the valuation of both companies to find out which one of these two is the better AI stock to buy right now. Given that DRAM accounted for 70% of Micron's total revenue in the previous fiscal year, the healthy prospects of this market bode well for the chipmaker.

Prospects 246
article thumbnail

This Unstoppable Biotech Stock Just Became an Even Better Buy

The Motley Fool

Now, Summit has recently made a move that could pay even more significant dividends down the road and improve its prospects. Let's see what that could mean for Summit Therapeutics' prospects. Summit's market capitalization of $15.3 Read on to find out more. Where to invest $1,000 right now?

Prospects 243
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Think AI's Prospects Are Overblown? Try This Beaten-Down Growth Stock.

The Motley Fool

While the prospect of LLMs autonomously completing multistep tasks is enticing, this may be a case of stretching a technology well beyond its capabilities. For companies relying on LLMs to write mission-critical code, it's questionable whether the technology will actually reduce costs given its tendency to produce errors.

Prospects 130
article thumbnail

C3.ai's CEO Says This May Have Been the "Most Significant Event in the Company's History"

The Motley Fool

Investors are bullish on its long-term prospects, given the company's varied AI services, which can attract customers from many different industries. ai's margins and prospects for profitability or if it will result in greater expenses and losses. AI Revenue (Quarterly) data by YCharts Instead, C3.ai's

Companies 246
article thumbnail

2 High-Yield Dividend Stocks That Are Bargain Buys Right Now

The Motley Fool

Pfizer looks attractive at these levels, considering its prospects. And in the long run, patent cliffs won't sink its prospects. Pfizer's forward price-to-earnings (P/E) ratio of 8.9 looks dirt cheap compared to the healthcare industry's average of 17.2. Golcadomide, another compound in development, is being studied in B-cell lymphoma.

Prospects 221
article thumbnail

This Consumer Staples Stock Could Be the Sweetest Investment of the Decade

The Motley Fool

Investors are, perhaps justifiably, not happy about that prospect. But that is set to end in 2025, with management projecting that adjusted earnings will decline between 30% and 40%. The second big headwind is a bit more nebulous.

Investing 246
article thumbnail

Better EV Stock: Rivian vs. Tesla

The Motley Fool

Or should one buy the dip in Tesla stock based on its existing profitability and prospects beyond its current EV lineup. Would it make sense to own Rivian with its strong and growing brand and high long-term potential?

Prospects 246